PRVCF

PreveCeutical Medical Inc

PRVCF, USA

PreveCeutical Medical Inc., a health sciences company, engages in the development of options for preventive and curative therapies utilizing organic and nature identical products. Its research and development programs include dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical peptides for treatment of various ailments; nonaddictive analgesic peptides as a replacement to the addictive analgesics, such as morphine, fentanyl, and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury). The company is headquartered in West Vancouver, Canada.

https://www.preveceutical.com

Stock Price

$0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
PRVCF
stock
PRVCF

PreveCeutical Medical and BioGene Therapeutics Announce Closing of Plan of Arrangement TMX Newsfile

Read more →
PRVCF
stock
PRVCF

PreveCeutical Provides Update on Plan of Arrangement with BioGene Therapeutics Inc. TMX Newsfile

Read more →

Showing 2 of 5

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Book Ratio (P/B)

-

Very Low

-1.28

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Low

11.53 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

-188.17 %

Low ≤ 2%

High ≥ 10%

Investors

* Institutions hold a combined 0.00% of the total shares of PreveCeutical Medical Inc

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

—

EPS Estimate

—

Latest Release

Date

2025-03-31

EPS Actual

-0.001

EPS Estimate

—

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Weak Deep Value(0.5)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(4.3)
GARP
Not Attractive for GARP(1)
Growth
Weak Growth Prospect(0.5)
Momentum
Moderate Momentum(3.5)
Net Net
Not Undervalued (Net-Net)(0.5)
Quality
Low Quality Business(1)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.